Triple-Negative Breast Cancer (TNBC) tends to be more aggressive, more likely to recur or spread, and more difficult to treat. This is because most chemotherapies target one cancerous receptor
Triple Negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors and Human Epidermal growth factor Receptor 2 (HER2) amplification…
Triple negative breast cancer (TNBC) is highly progressive and lacks established targets for therapeutic intervention. p38g mitogen-activated protein kinase (MAPK) (gene name: MAPK12) is overexpressed in TNBC…
Triple Negative Breast Cancer (TNBC) consists of very heterogeneous subgroups of breast cancers with significant clinical challenge, the prognosis and treatment of which remains poor and limited ... immune surveillance…
term triple negative breast cancer (TNBC) denotes those tumors which fail to express estrogen receptor (ER), progesterone receptor (PR) and human epidermal receptor (Her2) by immunohistochemical analysis and molecular…
subtypes, luminal A, luminal B, Her 2 positive cancer and triple negative breast cancer (TNBC/BLBC). It accounts for about 15-20% and among these TNBC accounts ... receptor negative were selected. Results: The total…
negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. TNBC is significantly observed in young African American women and Hispanic women who carry a mutation ... developing…
Mortality from triple negative breast cancer (TNBC) is significantly higher in African American (AA) women compared to White American (WA) women emphasizing ethnicity as a major risk factor; however ... molecular…
expression of breast tumors have come up with a term Triple-Negative Breast Cancer (TNBC), creating a phenotype and disease quite distinct from that seen in Triple-Positive Breast Cancer ... much more aggressive disease…
Triple negative breast cancer (TNBC) comprises 15-20% of breast cancer, and carries a poor prognosis. Recently, efforts to understand heterogeneous group of cancers - TNBC have succeed to recognize different…
effective at least in the early clinical course of triple-negative breast cancer (TNBC) patients but most eventually chemoresistance occur. Therefore, in this study, we assessed the panel of KI67 ... progression, in…
Triple Negative Breast Cancer (TNBC) is a highly heterogeneous and aggressive subtype of breast cancer. Tumor microenvironment has been identified as a major regulator of carcinogenesis and imparting drug resistance…
available for estrogen receptor positive and HER2-positive breast tumors, triple-negative breast cancer (TNBC) which are negative for ER, progesterone receptor PR and HER2 receptors lack targeted therapies. TNBC…
most common type of cancer among women, and Triple Negative Breast Cancer (TNBC) is a particularly aggressive subtype, representing 15%-20% of cases. TNBC lacks estrogen, progesterone, and HER2 receptors ... treat. This…
regulated result. Conclusion: Thymosin α1 down-regulates the PD-L1 expression of TNBC through the Wnt/β-catenin pathway, which may affect PD-L1-dependent TNBC immunotherapy
Caucasian women. Intriguingly, the aggressive and often fatal BC subtype, triple negative breast cancer (TNBC), is most common in young WAA but the reason for this racial disparity in TNBC ... found to correlate with…
BRCA1/2-negative BC families with 3.5-fold increased frequency among triple negative BC (TNBC) cases compared with controls. Given that deleterious mutations in other FA genes (BRCA2, RAD51C) have ... previously been…
first time, we discovered specific expression of ANX A2 in human TNBC cell lines. Minimal or no ANX A2 expression was detected in non-invasive ER positive breast cancer cell ... growth. We demonstrated that anti-ANX A2…
demonstrated role of glutamine in the growth and survival of Triple-Negative Breast Cancer (TNBC) cells, how glutamine is utilized in TNBC cells remains unclear. The tricarboxylic acid (TCA) cycle ... fulfills their…
mainstay therapy for the most intrusive-type of breast carcinoma, triple-negative breast cancer (TNBC) that has a higher tendency for visceral metastases, relapses, and poor prognoses. It is well ... developed at our…
reduces the effect of the drug(s) in cancer cells. Triple-negative breast cancer (TNBC) is an aggressive disease with a poor therapy outcome. Drug resistance and self-renewal properties ... urgent need to identify novel…
Triple negative breast cancer (TNBC) is a heterogeneous disease associated with poor clinical outcome and lack of targeted therapy. TNBC tumor cells are characterized by the loss of epithelial differentiation ... role…
prospectively confirm the influence of ICI infusions’ time-of-day on TNBC response to neoadjuvant treatment and explore the biological determinants behind it. CIRCADIAN is a prospective randomized clinical trial…
prospectively confirm the influence of ICI infusions' time-of-day on TNBC response to neoadjuvant treatment and explore the biological determinants behind it. CIRCADIAN is a prospective randomized clinical trial…
predict survival outcomes and identify potential therapeutic drugs for Triple-Negative Breast Cancer (TNBC) patients. Design: iTRAQ-based proteomics analysis of breast cancer tissues and bioinformatics analysis of the…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.